Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR Mutations

Introduction: Osimertinib (OSI), a third-generation EGFR tyrosine kinase inhibitor, is the standard treatment for patients with naive EGFR-mutant NSCLC. Nevertheless, information on how the mutation subtype affects disease progression after the failure of OSI treatment is scarce. Methods: We retrosp...

Full description

Bibliographic Details

Published in:	JTO Clinical and Research Reports
Main Authors:	Yuki Takeyasu, MD, Tatsuya Yoshida, MD, Ken Masuda, MD, Yuji Matsumoto, MD, Yuki Shinno, MD, Yusuke Okuma, MD, Yasushi Goto, MD, Hidehito Horinouchi, MD, Noboru Yamamoto, MD, Yuichiro Ohe, MD
Format:	Article
Language:	English
Published:	Elsevier 2024-02-01
Subjects:	Non–small cell lung cancer Epidermal growth factor receptor EGFR TKI Osimertinib Central nervous system
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666364324000067